LCC is transitioning from a CRO to a hub-and-spoke biotech company, generating small molecule lead candidate assets against oncology and rare disease targets. LCC built and validated its chemistry platform over 10 years via successful delivery across multiple target classes, including kinases, GPCRs, DUBs, and now mRNA small molecule targets.
Since 2014, LCC has built a successful fee-for-service business unit, and had their technology validated with clients that include 13 of the top 20 big pharma and >50 biotech companies. Now, the company’s PACE™ Platform is developing small molecule lead candidate assets, alongside strategic partners with biology-focused platforms. Chemistry platforms have traditionally taken a ‘big numbers’ (i.e., brute force) approach. They’ve designed larger and larger libraries, with mostly flat, aromatic, 2-dimensional fragments/components. However, LCC’s best-in-class chemistry platform is superior by intelligence of design. With a focus on component quality, the platform has been designed to include chemical space with increased 3D-character and assured chiral purity. Additionally, it offers:
- Increased novelty
- Increased diversity
- A proprietary ultra-large virtual chemical library (>1 billion) containing innovative lead and drug-like sp³-rich compounds covering novel chemical space with proven chemical tractability, enabled by synthesis-led design and parallel/automated synthesis.
LCC’s Chemistry Hub can be applied to multiple strategic partnership spokes, specializing in particular target classes and therapeutic areas in different geographical areas. The company has formed their first strategic partnership with Veritas in Silico, in which they are undergoing shared risk projects to discover and develop small molecule therapeutics against multiple mRNA targets and are in discussions with other potential strategic partners. 
“The LCC Team and I would like to thank everyone who has supported us along the way in reaching this key milestone. There are too many to name, but thank you to our investors (DeepBridge Capital, Praetura Ventures, and Maven Capital Partners) who have been with us during the last 10 years and are continuing to support us moving forward, the University of Liverpool, our collaborators, our clients, legal teams, past colleagues, and everyone else we have worked with. I’ll be sending personal thanks and will stay in touch as we move on to this next part of our journey, where we will be applying our PACE™ platform to accelerate the discovery of high-quality small molecule lead candidate assets for oncology and rare diseases.” – Paul Colbon, CEO & Co-Founder
If you think you could be a potential strategic partner or a potential investor, please get in touch with LCC at contact@liverpoolchirochem.com.
